GÖTTINGEN, Germany,
Nov. 2, 2020 /PRNewswire/ -- The life
science company Sartorius successfully closed the acquisition of
the Slovenian purification specialist BIA Separations. The
transaction was completed on November 2, 2020, after receiving
the required approvals.
"BIA´s portfolio is highly complementary to Sartorius. We are
thus creating an excellent offering for the manufacturing of gene
therapies and other advanced therapies, and are pleased to welcome
120 new employees," said Dr. Joachim
Kreuzburg, CEO of Sartorius.
The total purchase price of the transaction is 360 million euros of which 240 million euros were paid in cash and
120 million euros in Sartorius Stedim
Biotech shares. Both parties have further agreed on three tranches
of earn-out payments based on performance over the next five
financial years. Sartorius has been preparing to integrate BIA
Separations into the Sartorius Stedim Biotech subgroup so this can
now be initiated despite the special conditions prevailing during
the pandemic.
BIA Separations develops and manufactures market-leading
products for purification and analysis of large biomolecules, such
as viruses, plasmids and mRNA, which are used in cell and gene
therapies and other advanced therapies. BIA's technology for
manufacturing-scale purification is already used in production of
the first commercialized advanced therapeutics, and the company
also has a strong presence with such novel drug candidates in the
clinical pipeline. Expecting continued very strong double-digit
sales growth over the next few years, BIA is forecasted to earn
sales revenue of approx. 25 million
euros in 2020 at profit margins that will be accretive to
both the underlying EBITDA margins of Sartorius' Bioprocess
Solutions segment and of the overall Sartorius Group. The
transaction is not expected to have any material impact on
Sartorius' 2020 results.
This press release contains forward-looking statements about the
future development of the Sartorius Group. Forward-looking
statements are subject to known and unknown risks, uncertainties
and other factors that could cause actual results to differ
materially from those expressed or implied by such statements.
Sartorius assumes no liability for updating such statements in
light of new information or future events. This is a translation of
the original German-language press release. Sartorius shall not
assume any liability for the correctness of this translation. The
original German press release is the legally binding version.
A profile of Sartorius
The Sartorius Group is a leading international partner of life
science research and the biopharmaceutical industry. With
innovative laboratory instruments and consumables, the Group's Lab
Products & Services Division concentrates on serving the needs
of laboratories performing research and quality control at pharma
and biopharma companies and those of academic research institutes.
The Bioprocess Solutions Division with its broad product portfolio
focusing on single-use solutions helps customers to manufacture
biotech medications and vaccines safely and efficiently. The Group
has been annually growing by double digits on average and has been
regularly expanding its portfolio by acquisitions complementary
technologies. In fiscal 2019, the company earned sales revenue of
some 1.83 billion euros. At the end of 2019, more than 9,000
people were employed at the Group's approximately
60 manufacturing and sales sites, serving customers around the
globe.
Logo -
https://mma.prnewswire.com/media/1123369/Sartorius_Logo.jpg
Contact:
Andre Hofmann
Head of Public Relations
+49 (0)551.308.5096
andre.hofmann@sartorius.com
https://www.sartorius.com/en
Follow Sartorius on Twitter @Sartorius_Group and
on LinkedIn.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/sartorius-closes-acquisition-of-bia-separations-301165033.html
SOURCE SARTORIUS CORPORATE ADMINISTRATION GMBH